MedTrace Logo

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06819293 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-14

No results posted yet for this study

Summary

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Conditions

  • Advanced Clear Renal Cell Carcinoma
  • Adult

Interventions

BIOLOGICAL

IB-T101 injection

IB-T101 injection to treat advanced clear renal cell carcinoma

Sponsors & Collaborators

  • Grit Biotechnology

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-06
Primary Completion
2027-12-07
Completion
2027-12-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06819293 on ClinicalTrials.gov